Edinburgh Cancer Centre, NHS Lothian, Crewe Road South, Edinburgh, UK.
Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK.
Oncologist. 2023 Mar 17;28(3):e145-e155. doi: 10.1093/oncolo/oyac257.
Cancer and anti-cancer treatment (ACT) may be risk factors for severe SARS-CoV-2 infection and limited vaccine efficacy. Long-term longitudinal studies are needed to evaluate these risks. The Scottish COVID cancer immunity prevalence (SCCAMP) study characterizes the incidence and outcomes of SARS-CoV-2 infection and vaccination in patients with solid tumors undergoing ACT. This preliminary analysis includes 766 patients recruited since May 2020.
Patients with solid-organ cancers attending secondary care for active ACT consented to the collection of routine electronic health record data and serial blood samples over 12 months. Blood samples were tested for total SARS-CoV-2 antibody.
A total of 766 participants were recruited between May 28, 2020 and October 31, 2021. Most received cytotoxic chemotherapy (79%). Among the participants, 48 (6.3%) were tested positive for SARS-CoV-2 by PCR. Infection rates were unaffected by ACT, largely aligning with the local population. Mortality proportion was not higher with a recent positive SARS-CoV-2 PCR (10.4% vs 10.6%). Multivariate analysis revealed lower infection rates in vaccinated patients regardless of chemotherapy (HR 0.307 [95% CI, 0.144-0.6548]) or immunotherapy (HR 0.314 [95% CI, 0.041-2.367]) treatment. A total of 96.3% of patients successfully raised SARS-CoV-2 antibodies after >2 vaccines. This was independent of the treatment type.
This is the largest on-going longitudinal real-world dataset of patients undergoing ACT during the early stages of the COVID-19 pandemic. This preliminary analysis demonstrates that patients with solid tumors undergoing ACT have high protection from SARS-CoV-2 infection following COVID-19 vaccination. The SCCAMP study will evaluate long-term COVID-19 antibody trends, focusing on specific ACTs and patient subgroups.
癌症和抗癌治疗（ACT）可能是严重 SARS-CoV-2 感染和疫苗效力有限的风险因素。需要进行长期纵向研究来评估这些风险。苏格兰 COVID 癌症免疫流行率（SCCAMP）研究描述了正在接受 ACT 的实体瘤患者中 SARS-CoV-2 感染和疫苗接种的发生率和结局。本初步分析包括自 2020 年 5 月以来招募的 766 名患者。
正在接受 ACT 二级治疗的实体器官癌患者同意在 12 个月内收集常规电子健康记录数据和连续血液样本。血液样本检测总 SARS-CoV-2 抗体。
2020 年 5 月 28 日至 2021 年 10 月 31 日期间共招募 766 名参与者。大多数患者接受细胞毒性化疗（79%）。在参与者中，48 人（6.3%）经 PCR 检测 SARS-CoV-2 呈阳性。感染率不受 ACT 影响，与当地人群基本一致。近期 SARS-CoV-2 PCR 阳性患者的死亡率没有更高（10.4%比 10.6%）。多变量分析显示，无论是否接受化疗（HR 0.307[95%CI，0.144-0.6548]）或免疫治疗（HR 0.314[95%CI，0.041-2.367]），接种疫苗的患者感染率较低。>2 剂疫苗后，96.3%的患者成功产生 SARS-CoV-2 抗体。这与治疗类型无关。
这是 COVID-19 大流行早期正在接受 ACT 的患者的最大正在进行的纵向真实世界数据集。本初步分析表明，正在接受 ACT 的实体瘤患者在 COVID-19 接种疫苗后对 SARS-CoV-2 感染具有高度保护作用。SCCAMP 研究将评估 COVID-19 抗体的长期趋势，重点关注特定的 ACT 和患者亚组。
